Literature DB >> 10848227

Latanoprost and cystoid macular edema: is there a causal relation?

R A Schumer1, C B Camras, A K Mandahl.   

Abstract

Published reports of the occurrence of cystoid macular edema (CME) in eyes being treated with latanoprost have led to concern regarding a possible causal relation between the two. Review of all published cases (28 eyes in 25 patients), plus another case reported here for the first time, indicates that all eyes had independent risk for development of CME, so that definitive conclusions about a causal relation cannot be established. In addition, controlled clinical trials and experimental studies with latanoprost have given no indication that latanoprost causes clinical CME. Pharmacokinetic considerations indicate that the concentration of latanoprost expected in the posterior segment of the eye is too low to have a pharmacologic effect, and latanoprost is not known to exhibit vasoactive or inflammatory properties. Nevertheless, reports of a possible association between CME and latanoprost use must be given serious consideration, and in eyes that are at risk for CME, an increased level of surveillance for its development is recommended.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10848227     DOI: 10.1097/00055735-200004000-00005

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  13 in total

1.  Survey of perioperative prostaglandin analogue administration during cataract surgery in Greece.

Authors:  Asimina Mataftsi; Konstantinos T Tsaousis; Ioannis T Tsinopoulos; Stavros A Dimitrakos
Journal:  Int Ophthalmol       Date:  2012-03-20       Impact factor: 2.031

Review 2.  [General substance classification and pharmacology of glaucoma].

Authors:  H Thieme; G Renieri; C Schuart
Journal:  Ophthalmologe       Date:  2013-12       Impact factor: 1.059

Review 3.  Pharmacotherapy and Adherence Issues in Treating Elderly Patients with Glaucoma.

Authors:  David C Broadway; Heidi Cate
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

4.  Clinical utility and differential effects of prostaglandin analogs in the management of raised intraocular pressure and ocular hypertension.

Authors:  Anne J Lee; Peter McCluskey
Journal:  Clin Ophthalmol       Date:  2010-07-30

5.  Effects of AFP-172 on COX-2-induced angiogenic activities on human umbilical vein endothelial cells.

Authors:  Young Jung Roh; Young Gun Park; Seungbum Kang; Soo Young Kim; Jung Il Moon
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-08-22       Impact factor: 3.117

Review 6.  [Intraocular pressure related to uveitis].

Authors:  U Pleyer; P Ruokonen; C Heinz; A Heiligenhaus
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

Review 7.  Ocular hypertension following intravitreal anti-vascular endothelial growth factor agents.

Authors:  Ravi S J Singh; Judy E Kim
Journal:  Drugs Aging       Date:  2012-12       Impact factor: 3.923

Review 8.  Drug-induced macular edema.

Authors:  Olga E Makri; Ilias Georgalas; Constantine D Georgakopoulos
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

Review 9.  Latanoprost : an update of its use in glaucoma and ocular hypertension.

Authors:  Caroline M Perry; Jane K McGavin; Christine R Culy; Tim Ibbotson
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

10.  Topical latanoprost does not cause macular thickening after uncomplicated cataract surgery.

Authors:  Sasan Moghimi; Mehdi Zandian; Golshan Latifi; Heydar Amini; Yadollah Eslami; Reza Zarei; Ghasem Fakhraie; Kouros Nouri-Mahdavi
Journal:  J Ophthalmic Vis Res       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.